151
|
Brody J, Levy R. Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Immunotherapy 2009; 1:809-24. [PMID: 20636025 PMCID: PMC5469410 DOI: 10.2217/imt.09.50] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Therapy for non-Hodgkin lymphoma has benefited greatly from basic science and clinical research such that chemotherapy and monoclonal antibody therapy have changed some lymphoma subtypes from uniformly lethal to curable, but the majority of lymphoma patients remain incurable. Novel therapies with less toxicity and more specific targeting of tumor cells are needed and immunotherapy is among the most promising of these. Recently completed randomized trials of idiotype vaccines and earlier-phase trials of other vaccine types have shown the ability to induce antitumor T cells and some clinical responses. More recently, trials of adoptive transfer of antitumor T cells have demonstrated techniques to increase the persistence and antitumor effect of these cells. Herein, we discuss lymphoma immunotherapy clinical trial results and what lessons can be taken to improve their effect, including the combination of vaccination and adoptive transfer in an approach we have dubbed 'immunotransplant'.
Collapse
Affiliation(s)
- Joshua Brody
- Division of Oncology, Department of Medicine, Stanford University Medical Center, CA 94305, USA.
| | | |
Collapse
|
152
|
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113:6392-402. [PMID: 19377047 DOI: 10.1182/blood-2009-03-209650] [Citation(s) in RCA: 415] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
For the adoptive transfer of tumor-directed T lymphocytes to prove effective, there will probably need to be a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express. The Reed-Stemberg cells of Hodgkin lymphoma (HL) predominantly produce thymus- and activation-regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), which preferentially attract type 2 T helper (Th2) cells and regulatory T cells (Tregs) that express the TARC/MDC-specific chemokine receptor CCR4, thus generating an immunosuppressed tumor environment. By contrast, effector CD8(+) T cells lack CCR4, are nonresponsive to these chemokines and are rarely detected at the tumor site. We now show that forced expression of CCR4 by effector T cells enhances their migration to HL cells. Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 sustain their cytotoxic function and cytokine secretion in vitro, and produce enhanced tumor control when infused intravenously in mice engrafted with human HL. This approach may be of value in patients affected by HL.
Collapse
|
153
|
Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res 2009; 42:166-81. [PMID: 18841331 DOI: 10.1007/s12026-008-8057-6] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.
Collapse
Affiliation(s)
- Angel Varela-Rohena
- Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, 421 Curie Blvd-556 BRB II/III, Philadelphia, PA, 19104, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
154
|
Carpentier B, Pierobon P, Hivroz C, Henry N. T-cell artificial focal triggering tools: linking surface interactions with cell response. PLoS One 2009; 4:e4784. [PMID: 19274104 PMCID: PMC2653282 DOI: 10.1371/journal.pone.0004784] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Accepted: 02/12/2009] [Indexed: 12/22/2022] Open
Abstract
T-cell activation is a key event in the immune system, involving the interaction of several receptor ligand pairs in a complex intercellular contact that forms between T-cell and antigen-presenting cells. Molecular components implicated in contact formation have been identified, but the mechanism of activation and the link between molecular interactions and cell response remain poorly understood due to the complexity and dynamics exhibited by whole cell-cell conjugates. Here we demonstrate that simplified model colloids grafted so as to target appropriate cell receptors can be efficiently used to explore the relationship of receptor engagement to the T-cell response. Using immortalized Jurkat T cells, we monitored both binding and activation events, as seen by changes in the intracellular calcium concentration. Our experimental strategy used flow cytometry analysis to follow the short time scale cell response in populations of thousands of cells. We targeted both T-cell receptor CD3 (TCR/CD3) and leukocyte-function-associated antigen (LFA-1) alone or in combination. We showed that specific engagement of TCR/CD3 with a single particle induced a transient calcium signal, confirming previous results and validating our approach. By decreasing anti-CD3 particle density, we showed that contact nucleation was the most crucial and determining step in the cell-particle interaction under dynamic conditions, due to shear stress produced by hydrodynamic flow. Introduction of LFA-1 adhesion molecule ligands at the surface of the particle overcame this limitation and elucidated the low TCR/CD3 ligand density regime. Despite their simplicity, model colloids induced relevant biological responses which consistently echoed whole cell behavior. We thus concluded that this biophysical approach provides useful tools for investigating initial events in T-cell activation, and should enable the design of intelligent artificial systems for adoptive immunotherapy.
Collapse
Affiliation(s)
- Benoît Carpentier
- Institut Curie, Laboratoire Physico-Chimie Curie, CNRS UMR 168, Université Paris VI, Paris, France
| | - Paolo Pierobon
- Institut Curie, Laboratoire Physico-Chimie Curie, CNRS UMR 168, Université Paris VI, Paris, France
| | - Claire Hivroz
- Institut Curie, Laboratoire Immunité et Cancer, INSERM U 653, Pavillon Pasteur, Paris, France
| | - Nelly Henry
- Institut Curie, Laboratoire Physico-Chimie Curie, CNRS UMR 168, Université Paris VI, Paris, France
- * E-mail:
| |
Collapse
|
155
|
Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009; 157:9-19. [PMID: 19659765 DOI: 10.1111/j.1365-2249.2009.03912.x] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use.
Collapse
Affiliation(s)
- K S Peggs
- Department of Haematology, UCL Cancer Institute, Paul O'Gorman Building, University College London, London, UK.
| | | | | |
Collapse
|
156
|
Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. THE JOURNAL OF IMMUNOLOGY 2008; 181:4621-31. [PMID: 18802064 DOI: 10.4049/jimmunol.181.7.4621] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In malignancies where no universally expressed dominant Ag exists, the use of tumor cell-based vaccines has been proposed. We have modified a mouse neuroblastoma cell line to express either CD80 (B7.1), CD137L (4-1BBL), or both receptors on the tumor cell surface. Vaccines expressing both induce a strong T cell response that is unique in that among responding CD8 T cells, a T effector memory cell (T(EM)) response arises in which a large number of the T(EM) express the alpha-chain of VLA-2, CD49b. We demonstrate using both in vitro and in vivo assays that the CD49b(+) CD8 T cell population is a far more potent antitumor effector cell population than nonfractionated CD8 or CD49b(-) CD8 T cells and that CD49b on vaccine-induced CD8 T cells mediates invasion of a collagen matrix. In in vivo rechallenge studies, CD49b(+) T cells no longer expanded, indicating that CD49b T(EM) expansion is restricted to the initial response to vaccine. To demonstrate a mechanistic link between the expression of costimulatory molecules on the vaccine and CD49b on responding T cells, we stimulated naive T cells in vitro with artificial APC expressing different combinations of anti-CD3, anti-CD28, and CD137L. Although some mRNA encoding CD49b was induced by combining anti-CD3 with anti-CD28 or CD137L, the highest level was induced when all three signals were present. This indicates that CD49b expression results from additive costimulation and that the level of CD49b message serves as an indicator of the effectiveness of T cell activation by a cell-based vaccine.
Collapse
Affiliation(s)
- Xiaocai Yan
- Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin Milwaukee, WI 53226, USA
| | | | | |
Collapse
|
157
|
Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L. Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J 2008; 49:192-200. [PMID: 18461674 DOI: 10.3325/cmj.2008.2.192] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
AIM To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity. METHODS Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma). The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction. To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells. RESULTS The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12). CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells. The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors. Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8. CONCLUSION CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
Collapse
Affiliation(s)
- Qun Wang
- Department of Immunology, Shandong University School of Medicine, Jinan, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
158
|
Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol 2008; 384:1143-56. [PMID: 18809410 DOI: 10.1016/j.jmb.2008.09.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2008] [Revised: 08/29/2008] [Accepted: 09/03/2008] [Indexed: 11/16/2022]
Abstract
In humans, NKG2D is an activating receptor on natural killer (NK) cells and a costimulatory receptor on certain T cells and plays a central role in mediating immune responses in autoimmune diseases, infectious diseases, and cancer. Monoclonal antibodies that antagonize or agonize immune responses mediated by human NKG2D are considered to be of broad and potent therapeutic utility. Nonetheless, monoclonal antibodies to NKG2D that are suitable for clinical investigations have not been published yet. Here, we describe the generation, affinity maturation, and characterization of a fully human monoclonal antibody to human NKG2D. Using phage display technology based on a newly generated naïve human Fab library in phage display vector pC3C followed by a tandem chain shuffling process designed for minimal deviation from natural human antibody sequences, we selected a human Fab, designated KYK-2.0, with high specificity and affinity to human NKG2D. KYK-2.0 Fab blocked the binding of the natural human NKG2D ligands MICA, MICB, and ULBP2 as potently as a commercially available mouse anti-human NKG2D monoclonal antibody in immunoglobulin G (IgG) format. Conversion of KYK-2.0 Fab to IgG1 resulted in subnanomolar avidity for human NKG2D. KYK-2.0 IgG1 was found to selectively recognize defined subpopulations of human lymphocytes known to express NKG2D, that is, the majority of human CD8+, CD16+, and CD56+ cells as well as a small fraction of human CD4+ cells. In solution, KYK-2.0 IgG1 interfered with the cytolytic activity of ex vivo expanded human NK cells. By contrast, immobilized KYK-2.0 IgG1 was found to strongly induce human NK cell activation. The dual antagonistic and agonistic activity promises a wide range of therapeutic applications for KYK-2.0 IgG1 and its derivatives.
Collapse
Affiliation(s)
- Ka Yin Kwong
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | |
Collapse
|
159
|
Caserta S, Alessi P, Guarnerio J, Basso V, Mondino A. Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses. Cancer Res 2008; 68:3010-8. [PMID: 18413771 DOI: 10.1158/0008-5472.can-07-5796] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
CD4(+) helper T cells are critical for protective immune responses and yet suboptimally primed in response to tumors. Cell-based vaccination strategies are under evaluation in clinical trials but limited by the need to derive antigen-presenting cells (APC) from patients or compatible healthy donors. To overcome these limitations, we developed CD4(+) T cell-targeted synthetic microbead-based artificial APC (aAPC) and used them to activate CD4(+) T lymphocytes specific for a tumor-associated model antigen (Ag) directly from the naive repertoire. In vitro, aAPC specifically primed Ag-specific CD4(+) T cells that were activated to express high levels of CD44, produced mainly interleukin 2, and could differentiate into Th1-like or Th2-like cells in combination with polarizing cytokines. I.v. administration of aAPC led to Ag-specific CD4(+) T-cell activation and proliferation in secondary lymphoid organs, conferred partial protection against subcutaneous tumors, and prevented the establishment of lung metastasis. Taken together, our data support the use of cell-free, synthetic aAPC as a specific and versatile alternative to expand peptide-specific CD4(+) T cells in adoptive and active immunotherapy.
Collapse
Affiliation(s)
- Stefano Caserta
- Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, Milan, Italy
| | | | | | | | | |
Collapse
|
160
|
Suhoski MM, Perez EE, Heltzer ML, Laney A, Shaffer LG, Saitta S, Nachman S, Spinner NB, June CH, Orange JS. Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. Clin Immunol 2008; 128:181-9. [PMID: 18511345 DOI: 10.1016/j.clim.2008.03.522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2007] [Revised: 03/25/2008] [Accepted: 03/29/2008] [Indexed: 10/22/2022]
Abstract
Monosomy 1p36 is a subtelomeric deletion syndrome associated with congenital anomalies presumably due to haploinsufficiency of multiple genes. Although immunodeficiency has not been reported, genes encoding costimulatory molecules of the TNF receptor superfamily (TNFRSF) are within 1p36 and may be affected. In one patient with monosomy 1p36, comparative genome hybridization and fluorescence in- situ hybridization confirmed that TNFRSF member OX40 was included within the subtelomeric deletion. T cells from this patient had decreased OX40 expression after stimulation. Specific, ex vivo T cell activation through OX40 revealed enhanced proliferation, and reduced viability of patient CD4+ T cells, providing evidence for the association of monosomy 1p36 with reduced OX40 expression, and decreased OX40-induced T cell survival. These results support a role for OX40 in human immunity, and calls attention to the potential for haploinsufficiency deletions of TNFRSF costimulatory molecules in monosomy 1p36.
Collapse
Affiliation(s)
- M M Suhoski
- Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, PA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
161
|
Guo H, Jiang W, Liu W, Gao Y, Yang M, Zhou Y, Wang J, Qi J, Cheng X, Zhu Z, Yang C, Xiong D. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol 2008; 251:102-8. [PMID: 18482719 DOI: 10.1016/j.cellimm.2008.04.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 03/28/2008] [Accepted: 04/04/2008] [Indexed: 11/18/2022]
Abstract
Our previous data have shown a significantly higher tumor response to anti-CD3/anti-Pgp bispecific diabody-mediated immunotherapy for P-glycoprotein (Pgp)-overexpressing K562/A02 cells, but a rapid tumor relapse occurred at 1 week after therapy. In an attempt to overcome tumor recurrence, we supplemented the previous therapy with extracellular domain of human 4-1BBL (ex4-1BBL) to regulate the activation of peripheral blood lymphocyte (PBL). As a result, this combination showed enhanced cytotoxicity in vitro and eradicated the multidrug-resistant xenografts of K562/A02 in nude mice. Furthermore, no tumor recurrence was observed within 100 days after the first treatment. Therefore, when used as an adjuvant, ex4-1BBL may improve the outcome of PBL-based immunotherapy.
Collapse
Affiliation(s)
- Hongxing Guo
- State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Science, Peking Union Medical College, Tianjin, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
162
|
Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ, Levine BL, Carroll RG, Riley JL, June CH. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 2008; 42:182-96. [PMID: 18949448 PMCID: PMC3809041 DOI: 10.1007/s12026-008-8070-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Many recent advances in basic cell biology and immunology are a harbinger of progress in adoptive cell therapy (ACT) including (1) the finding that host lymphodepletion enhances engraftment and efficacy, (2) the recognition that in vitro T cell functions may not correlate with in vivo efficacy, and (3) the development of advanced ex vivo culture methods to expand lymphocytes to therapeutically effective numbers. In this article, we focus on the development of artificial antigen presenting cells (aAPCs) in our laboratory and their applicability to augment ACT protocols. We also describe how aAPCs can be used to broaden ACT to treat patients with a wide variety of cancers, chronic infectious diseases, and autoimmune manifestations.
Collapse
Affiliation(s)
- Chrystal M. Paulos
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Megan M. Suhoski
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Gabriela Plesa
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Tianying Jiang
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Samik Basu
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Tatiana N. Golovina
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Shuguang Jiang
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Nicole A. Aqui
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, 421 Curie Blvd – 543BRB II/III, Philadelphia, PA 19104, USA
| | - Daniel J. Powell
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - Bruce L. Levine
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, 421 Curie Blvd – 543BRB II/III, Philadelphia, PA 19104, USA
| | - Richard G. Carroll
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
| | - James L. Riley
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, 421 Curie Blvd – 543BRB II/III, Philadelphia, PA 19104, USA
| | - Carl H. June
- Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, 421 Curie Blvd – 543BRB II/III, Philadelphia, PA 19104, USA
| |
Collapse
|